<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336450</url>
  </required_header>
  <id_info>
    <org_study_id>SHP615-302</org_study_id>
    <nct_id>NCT03336450</nct_id>
  </id_info>
  <brief_title>Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is&#xD;
      safe and effective in children with status epilepticus (SE) (convulsive) in the community&#xD;
      setting. This study is open-label extension for patients who completed the SHP615-301 study&#xD;
      and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">October 13, 2020</completion_date>
  <primary_completion_date type="Actual">October 13, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Number of Participants With Therapeutic Success</measure>
    <time_frame>From start of study drug administration up to 30 minutes post-dose</time_frame>
    <description>Therapeutic success was defined as cessation of visible seizure activity within 10 minutes and sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615 without the need for additional rescue medication. Number of participants with therapeutic success were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Participants With Respiratory Depression</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
    <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt;92 percent (%) measured up to 24 hours post-dose (i.e., &lt;92% on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]. ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours</measure>
    <time_frame>From start of study drug administration up to 1, 4, and 6 hours post-dose</time_frame>
    <description>Number of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time to Resolution of Seizures (Convulsions)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>Time to resolution of seizures (convulsions) was calculated as time from SHP615 administration to the end of the initial seizure or administration of rescue anticonvulsant medication, whichever occurs first. The initial seizure refers to the seizure which triggered the use of the IP. Participant wise data was reported for this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time to Recovery of Consciousness</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>Time to recovery of consciousness in minutes was calculated only for participants who lost consciousness pre-dose as time from SHP615 administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Participant wise data was reported for this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of SHP615 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615</measure>
    <time_frame>10 minutes post-dose</time_frame>
    <description>Treatment failure/non-responder was defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of SHP615 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>TEAEs was defined as adverse events (AEs) whose onset occurs, severity worsens or intensity increases on or after the date of SHP615 administration. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale</measure>
    <time_frame>1, 4, 6, and 24 hours post-dose</time_frame>
    <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Number of participants analyzed for sedation or agitation measured by the riker sedation-agitation scale were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 6 hours post-dose</time_frame>
    <description>TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Buccal cavity was examined for redness, inflammation and ulceration. Number of participants with buccal irritation reported as TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Number of participants with TEAEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs</measure>
    <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
    <description>Vital sign assessments included blood pressure, pulse, respiratory rate and body temperature. Any change in vital signs which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs</measure>
    <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
    <description>Clinical laboratory evaluations included biochemistry, endocrinology, hematology and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs</measure>
    <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
    <description>12-lead ECG were evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator were reported as TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting</measure>
    <time_frame>0.5, 1, 4, 6 and 24 hours post-dose</time_frame>
    <description>Oxygen saturation is the amount of oxygen that is in bloodstream and is measured as the percentage of blood hemoglobin that is carrying oxygen. Normal oxygen saturation levels are considered to be 95-100 percent; low oxygen saturation values indicate worse disease. Oxygen saturation was measured and recorded on room air. The investigator recorded the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered during hospital setting. Percentage of participants with normal oxygen saturation values collected during hospital setting were reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>SHP615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP615</intervention_name>
    <description>SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).</description>
    <arm_group_label>SHP615</arm_group_label>
    <other_name>MHOS</other_name>
    <other_name>Midazolam hydrochloride oromucosal solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHOS/SHP615</intervention_name>
    <description>MHOS/SHP615</description>
    <arm_group_label>SHP615</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who completed the SHP615-301 study and who tolerated and responded to&#xD;
             treatment with MHOS/SHP615 in the hospital and/or emergency room, and are considered&#xD;
             stable for discharge from the hospital.&#xD;
&#xD;
          -  Subjects who are greater than (&gt;) 6 months and less than (&lt;) 18 years of age at the&#xD;
             time of investigational product administration. If the subject's exact age is not&#xD;
             known, the subject should be excluded.&#xD;
&#xD;
          -  Parent, guardian, or legally authorized representative of the child who provides&#xD;
             informed consent and assent (when applicable) to participate in the study after&#xD;
             initial stabilization of the subject with SE in hospital or emergency room during the&#xD;
             SHP615-301 study. The subject also provides informed consent prior to participation,&#xD;
             where applicable.&#xD;
&#xD;
          -  Parent, guardian, or legally authorized representative who have received appropriate&#xD;
             training/education and are deemed qualified by the investigator and are willing to:&#xD;
&#xD;
               1. Properly administer MHOS/SHP615.&#xD;
&#xD;
               2. Record seizure information and dosing of MHOS/SHP615 in a subject diary&#xD;
                  (including time of seizure onset, type of seizure, time necessary to administer&#xD;
                  MHOS/SHP615, time between MHOS/SHP615 administration to seizure cessation, etc.)&#xD;
&#xD;
               3. Follow the necessary instructions to secure the safety of the subject.&#xD;
&#xD;
          -  Subjects who experience generalized tonic-clonic SE with seizures accompanied by loss&#xD;
             of consciousness with any of the following characteristics persistent at the time of&#xD;
             study drug administration:&#xD;
&#xD;
               1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions&#xD;
                  within the preceding hour&#xD;
&#xD;
               2. Currently presenting with seizure (convulsive) and 2 or more convulsions in&#xD;
                  succession without recovery of consciousness.&#xD;
&#xD;
               3. Currently presenting with a single seizure (convulsive) persisting greater than&#xD;
                  or equal to (&gt;=) 5 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, suspected to be pregnant, or nursing.&#xD;
&#xD;
          -  Subjects with major trauma, not necessarily restricted to the head, as the cause of&#xD;
             the seizure.&#xD;
&#xD;
          -  Subjects with known or suspected recurrent seizures due to illegal drug or alcohol&#xD;
             withdrawal.&#xD;
&#xD;
          -  Subjects with seizures due to illegal drug or acute alcoholic intoxication.&#xD;
&#xD;
          -  Subjects with seizures of psychogenic origin.&#xD;
&#xD;
          -  Subjects with seizures due to severe encephalitis or meningitis, as determined by the&#xD;
             PI&#xD;
&#xD;
          -  Subjects with known history of hypersensitivities, nonresponsiveness or&#xD;
             contraindications to benzodiazepines (that is (ie), clinically significant respiratory&#xD;
             depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea,&#xD;
             glaucoma with closed angle, or use of concomitant drugs determined by the investigator&#xD;
             to have a contraindication to the use of benzodiazepines.)&#xD;
&#xD;
          -  Subjects with a known history of benzodiazepine abuse.&#xD;
&#xD;
          -  Subjects who have not responded to previous administrations of midazolam systemic&#xD;
             therapies, including MIDAFRESA and/or DORMICUM.&#xD;
&#xD;
          -  Subjects who need emergent surgical intervention and general anesthesia/intubation.&#xD;
&#xD;
          -  Subjects who have been receiving human immunodeficiency virus (HIV) protease&#xD;
             inhibitors or HIV reverse transcriptase inhibitors.&#xD;
&#xD;
          -  Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the&#xD;
             healthcare provider.&#xD;
&#xD;
          -  Have used an investigational product or been enrolled in a clinical study (including&#xD;
             vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored&#xD;
             study.&#xD;
&#xD;
          -  Subject has prior placement of a vagus nerve stimulator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>216 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Development Center Americas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Fujimi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Minami-Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <state>Okayama Prefecture</state>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Owada Shinden</state>
        <zip>276-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Institute of Epilepsy and Neurological Disorders</name>
      <address>
        <city>Shizuoka</city>
        <state>Shizuoka Prefecture</state>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital(NW)</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Hokkaido Medical Center</name>
      <address>
        <city>Hokkaid≈ç</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nishi Niigata Chuo National Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center(NW)</name>
      <address>
        <city>Obu</city>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0914</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakano Children's Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>535-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital(NW)</name>
      <address>
        <city>Osaka</city>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Children's Medical Center Tochigi</name>
      <address>
        <city>Saitama-shi</city>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center(NW)</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center Hospital, NCNP</name>
      <address>
        <city>Tokyo</city>
        <zip>187-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Yamadaoka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center(NW)</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <results_first_submitted>June 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2021</results_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03336450/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03336450/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 27 centers in Japan between 23 April 2018 (first participant first visit) and 13 October 2020 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 12 participants were screened, of which 9 participants were screen failures and withdrawn prior to randomization. Only 3 participants were enrolled to receive treatment and completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set consisted of all participants who had received a single dose of Investigational product (IP), regardless of whether the study drug administration was documented to be complete or not on the study drug administration electronic case report form (eCRF).</population>
      <group_list>
        <group group_id="B1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.07" spread="1.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Number of Participants With Therapeutic Success</title>
        <description>Therapeutic success was defined as cessation of visible seizure activity within 10 minutes and sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615 without the need for additional rescue medication. Number of participants with therapeutic success were reported.</description>
        <time_frame>From start of study drug administration up to 30 minutes post-dose</time_frame>
        <population>Full analysis set (FAS) consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Number of Participants With Therapeutic Success</title>
          <description>Therapeutic success was defined as cessation of visible seizure activity within 10 minutes and sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615 without the need for additional rescue medication. Number of participants with therapeutic success were reported.</description>
          <population>Full analysis set (FAS) consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours</title>
        <description>Number of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
        <time_frame>From start of study drug administration up to 1, 4, and 6 hours post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Number of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4, and 6 Hours</title>
          <description>Number of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sustained absence for at least 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained absence for at least 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained absence for at least 6 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Time to Resolution of Seizures (Convulsions)</title>
        <description>Time to resolution of seizures (convulsions) was calculated as time from SHP615 administration to the end of the initial seizure or administration of rescue anticonvulsant medication, whichever occurs first. The initial seizure refers to the seizure which triggered the use of the IP. Participant wise data was reported for this outcome.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP. Here, number analyzed signifies participants who were evaluable for this specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Time to Resolution of Seizures (Convulsions)</title>
          <description>Time to resolution of seizures (convulsions) was calculated as time from SHP615 administration to the end of the initial seizure or administration of rescue anticonvulsant medication, whichever occurs first. The initial seizure refers to the seizure which triggered the use of the IP. Participant wise data was reported for this outcome.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP. Here, number analyzed signifies participants who were evaluable for this specific category.</population>
          <units>Minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Time to Recovery of Consciousness</title>
        <description>Time to recovery of consciousness in minutes was calculated only for participants who lost consciousness pre-dose as time from SHP615 administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Participant wise data was reported for this outcome.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP. Here, number analyzed signifies participants who were evaluable for this specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Time to Recovery of Consciousness</title>
          <description>Time to recovery of consciousness in minutes was calculated only for participants who lost consciousness pre-dose as time from SHP615 administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Participant wise data was reported for this outcome.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP. Here, number analyzed signifies participants who were evaluable for this specific category.</population>
          <units>Minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615</title>
        <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of SHP615 were reported.</description>
        <time_frame>10 minutes post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) 10 Minutes After Administration of SHP615</title>
          <description>Percentage of participants who required additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of SHP615 were reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615</title>
        <description>Treatment failure/non-responder was defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of SHP615 was reported.</description>
        <time_frame>10 minutes post-dose</time_frame>
        <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Participants Who Failed to Respond to Treatment With SHP615</title>
          <description>Treatment failure/non-responder was defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of SHP615 was reported.</description>
          <population>FAS consisted of all participants in the safety set who had at least 1 assessment for determination of therapeutic success (cessation of seizure within 10 minutes with sustained absence of seizure for 30 minutes) performed after the administration of IP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Number of Participants With Respiratory Depression</title>
        <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt;92 percent (%) measured up to 24 hours post-dose (i.e., &lt;92% on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]. ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
        <time_frame>Up to 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Respiratory Depression</title>
          <description>Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to &lt;92 percent (%) measured up to 24 hours post-dose (i.e., &lt;92% on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]. ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs was defined as adverse events (AEs) whose onset occurs, severity worsens or intensity increases on or after the date of SHP615 administration. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs was defined as adverse events (AEs) whose onset occurs, severity worsens or intensity increases on or after the date of SHP615 administration. Number of participants with aspiration pneumonia identified as TEAEs were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale</title>
        <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Number of participants analyzed for sedation or agitation measured by the riker sedation-agitation scale were reported.</description>
        <time_frame>1, 4, 6, and 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants Analyzed for Sedation or Agitation Measured by the Riker Sedation-Agitation Scale</title>
          <description>Sedation-Agitation was assessed, using the &quot;Riker Sedation-Agitation Scale&quot; (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Number of participants analyzed for sedation or agitation measured by the riker sedation-agitation scale were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant with unarousable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with very sedated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with sedated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with calm and cooperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with agitated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with very agitated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with dangerous agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Buccal cavity was examined for redness, inflammation and ulceration. Number of participants with buccal irritation reported as TEAEs were reported.</description>
        <time_frame>Up to 6 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Buccal Irritation Reported as Treatment Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Buccal cavity was examined for redness, inflammation and ulceration. Number of participants with buccal irritation reported as TEAEs were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Number of participants with TEAEs were reported.</description>
        <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs whose onset occurs, severity worsens or intensity increases on or after the date of IP administration. Number of participants with TEAEs were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs</title>
        <description>Vital sign assessments included blood pressure, pulse, respiratory rate and body temperature. Any change in vital signs which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
        <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Clinically Significant Change in Vital Signs Reported as TEAEs</title>
          <description>Vital sign assessments included blood pressure, pulse, respiratory rate and body temperature. Any change in vital signs which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs</title>
        <description>Clinical laboratory evaluations included biochemistry, endocrinology, hematology and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
        <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as TEAEs</title>
          <description>Clinical laboratory evaluations included biochemistry, endocrinology, hematology and urinalysis. Any change in clinical laboratory abnormalities which were deemed clinically significant by the investigator were recorded as TEAEs.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs</title>
        <description>12-lead ECG were evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator were reported as TEAEs.</description>
        <time_frame>From start of study drug administration up to 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as TEAEs</title>
          <description>12-lead ECG were evaluated. Any change in ECG assessments which are deemed clinically significant by the investigator were reported as TEAEs.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting</title>
        <description>Oxygen saturation is the amount of oxygen that is in bloodstream and is measured as the percentage of blood hemoglobin that is carrying oxygen. Normal oxygen saturation levels are considered to be 95-100 percent; low oxygen saturation values indicate worse disease. Oxygen saturation was measured and recorded on room air. The investigator recorded the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered during hospital setting. Percentage of participants with normal oxygen saturation values collected during hospital setting were reported.</description>
        <time_frame>0.5, 1, 4, 6 and 24 hours post-dose</time_frame>
        <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
        <group_list>
          <group group_id="O1">
            <title>SHP615</title>
            <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Percentage of Participants With Normal Oxygen Saturation Values Collected During Hospital Setting</title>
          <description>Oxygen saturation is the amount of oxygen that is in bloodstream and is measured as the percentage of blood hemoglobin that is carrying oxygen. Normal oxygen saturation levels are considered to be 95-100 percent; low oxygen saturation values indicate worse disease. Oxygen saturation was measured and recorded on room air. The investigator recorded the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered during hospital setting. Percentage of participants with normal oxygen saturation values collected during hospital setting were reported.</description>
          <population>Safety set consisted of all participants who had received a single dose of IP, regardless of whether the study drug administration was documented to be complete or not on the study drug administration eCRF.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to follow-up (Day 8)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SHP615</title>
          <description>Participants received single fixed age-specific dose (6 months to less than [&lt;] 1 year received 2.5 milligrams [mg]; 1 to &lt; 5 years received 5 mg; 5 to &lt;10 years received 7.5 mg and 10 to &lt; 18 years received 10 mg) of midazolam hydrochloride oromucosal solution (MHOS)/SHP615 buccally by caregivers on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

